Cargando…

Surveillance nanotechnology for multi-organ cancer metastases

The identification and molecular profiling of early metastases remains a major challenge in cancer diagnostics and therapy. Most in vivo imaging methods fail to detect small cancerous lesions, a problem that is compounded by the distinct physical and biological barriers associated with different met...

Descripción completa

Detalles Bibliográficos
Autores principales: Kantamneni, Harini, Zevon, Margot, Donzanti, Michael J., Zhao, Xinyu, Sheng, Yang, Barkund, Shravani R., McCabe, Lucas H., Banach-Petrosky, Whitney, Higgins, Laura M., Ganesan, Shridar, Riman, Richard E., Roth, Charles M., Tan, Mei-Chee, Pierce, Mark C., Ganapathy, Vidya, Moghe, Prabhas V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844578/
https://www.ncbi.nlm.nih.gov/pubmed/29531851
http://dx.doi.org/10.1038/s41551-017-0167-9
_version_ 1783305259913838592
author Kantamneni, Harini
Zevon, Margot
Donzanti, Michael J.
Zhao, Xinyu
Sheng, Yang
Barkund, Shravani R.
McCabe, Lucas H.
Banach-Petrosky, Whitney
Higgins, Laura M.
Ganesan, Shridar
Riman, Richard E.
Roth, Charles M.
Tan, Mei-Chee
Pierce, Mark C.
Ganapathy, Vidya
Moghe, Prabhas V.
author_facet Kantamneni, Harini
Zevon, Margot
Donzanti, Michael J.
Zhao, Xinyu
Sheng, Yang
Barkund, Shravani R.
McCabe, Lucas H.
Banach-Petrosky, Whitney
Higgins, Laura M.
Ganesan, Shridar
Riman, Richard E.
Roth, Charles M.
Tan, Mei-Chee
Pierce, Mark C.
Ganapathy, Vidya
Moghe, Prabhas V.
author_sort Kantamneni, Harini
collection PubMed
description The identification and molecular profiling of early metastases remains a major challenge in cancer diagnostics and therapy. Most in vivo imaging methods fail to detect small cancerous lesions, a problem that is compounded by the distinct physical and biological barriers associated with different metastatic niches. Here, we show that intravenously injected rare-earth-doped albumin-encapsulated nanoparticles emitting short-wave infrared light (SWIR) can detect targeted metastatic lesions in vivo, allowing for the longitudinal tracking of multi-organ metastases. In a murine model of basal human breast cancer, the nanoprobes enabled whole-body SWIR detection of adrenal gland microlesions and bone lesions that were undetectable via contrast-enhanced magnetic resonance imaging (CE-MRI) as early as, respectively, three weeks and five weeks post-inoculation. Whole-body SWIR imaging of nanoprobes functionalized to differentially target distinct metastatic sites and administered to a biomimetic murine model of human breast cancer resolved multi-organ metastases that showed varied molecular profiles at the lungs, adrenal glands and bones. Real-time surveillance of lesions in multiple organs should facilitate pre-therapy and post-therapy monitoring in preclinical settings.
format Online
Article
Text
id pubmed-5844578
institution National Center for Biotechnology Information
language English
publishDate 2017
record_format MEDLINE/PubMed
spelling pubmed-58445782018-06-12 Surveillance nanotechnology for multi-organ cancer metastases Kantamneni, Harini Zevon, Margot Donzanti, Michael J. Zhao, Xinyu Sheng, Yang Barkund, Shravani R. McCabe, Lucas H. Banach-Petrosky, Whitney Higgins, Laura M. Ganesan, Shridar Riman, Richard E. Roth, Charles M. Tan, Mei-Chee Pierce, Mark C. Ganapathy, Vidya Moghe, Prabhas V. Nat Biomed Eng Article The identification and molecular profiling of early metastases remains a major challenge in cancer diagnostics and therapy. Most in vivo imaging methods fail to detect small cancerous lesions, a problem that is compounded by the distinct physical and biological barriers associated with different metastatic niches. Here, we show that intravenously injected rare-earth-doped albumin-encapsulated nanoparticles emitting short-wave infrared light (SWIR) can detect targeted metastatic lesions in vivo, allowing for the longitudinal tracking of multi-organ metastases. In a murine model of basal human breast cancer, the nanoprobes enabled whole-body SWIR detection of adrenal gland microlesions and bone lesions that were undetectable via contrast-enhanced magnetic resonance imaging (CE-MRI) as early as, respectively, three weeks and five weeks post-inoculation. Whole-body SWIR imaging of nanoprobes functionalized to differentially target distinct metastatic sites and administered to a biomimetic murine model of human breast cancer resolved multi-organ metastases that showed varied molecular profiles at the lungs, adrenal glands and bones. Real-time surveillance of lesions in multiple organs should facilitate pre-therapy and post-therapy monitoring in preclinical settings. 2017-12-12 2017 /pmc/articles/PMC5844578/ /pubmed/29531851 http://dx.doi.org/10.1038/s41551-017-0167-9 Text en Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use: http://www.nature.com/authors/editorial_policies/license.html#terms
spellingShingle Article
Kantamneni, Harini
Zevon, Margot
Donzanti, Michael J.
Zhao, Xinyu
Sheng, Yang
Barkund, Shravani R.
McCabe, Lucas H.
Banach-Petrosky, Whitney
Higgins, Laura M.
Ganesan, Shridar
Riman, Richard E.
Roth, Charles M.
Tan, Mei-Chee
Pierce, Mark C.
Ganapathy, Vidya
Moghe, Prabhas V.
Surveillance nanotechnology for multi-organ cancer metastases
title Surveillance nanotechnology for multi-organ cancer metastases
title_full Surveillance nanotechnology for multi-organ cancer metastases
title_fullStr Surveillance nanotechnology for multi-organ cancer metastases
title_full_unstemmed Surveillance nanotechnology for multi-organ cancer metastases
title_short Surveillance nanotechnology for multi-organ cancer metastases
title_sort surveillance nanotechnology for multi-organ cancer metastases
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5844578/
https://www.ncbi.nlm.nih.gov/pubmed/29531851
http://dx.doi.org/10.1038/s41551-017-0167-9
work_keys_str_mv AT kantamneniharini surveillancenanotechnologyformultiorgancancermetastases
AT zevonmargot surveillancenanotechnologyformultiorgancancermetastases
AT donzantimichaelj surveillancenanotechnologyformultiorgancancermetastases
AT zhaoxinyu surveillancenanotechnologyformultiorgancancermetastases
AT shengyang surveillancenanotechnologyformultiorgancancermetastases
AT barkundshravanir surveillancenanotechnologyformultiorgancancermetastases
AT mccabelucash surveillancenanotechnologyformultiorgancancermetastases
AT banachpetroskywhitney surveillancenanotechnologyformultiorgancancermetastases
AT higginslauram surveillancenanotechnologyformultiorgancancermetastases
AT ganesanshridar surveillancenanotechnologyformultiorgancancermetastases
AT rimanricharde surveillancenanotechnologyformultiorgancancermetastases
AT rothcharlesm surveillancenanotechnologyformultiorgancancermetastases
AT tanmeichee surveillancenanotechnologyformultiorgancancermetastases
AT piercemarkc surveillancenanotechnologyformultiorgancancermetastases
AT ganapathyvidya surveillancenanotechnologyformultiorgancancermetastases
AT mogheprabhasv surveillancenanotechnologyformultiorgancancermetastases